IP Library Granted Patent US 10,590,059
Granted Patent B2
US 10,590,059 · App. 16/194,141 · Granted Mar 17, 2020

Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids

Inventors: Roshantha A. Chandraratna (San Juan Capistrano, CA); Vidyasagar Pradeep Vuligonda (Irvine, CA); Thomas Jacks (South Plainfield, NJ); Peter Wade (South Plainfield, NJ); Andrew Thompson (South Plainfield, NJ)
Assignee: Io Therapeutics, Inc.
C07C57/50A61K31/192A61K31/198C07C29/44C07C33/36C07C33/38C07C51/255C07B2200/07C07C2601/02C07C2602/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,590,059
App. No.
16/194,141
Granted
Mar 17, 2020
Kind
B2
Abstract

Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity. Also provided herein are processes for the preparation of compounds that have retinoid-like biological activity.

Claims (87)

1. A method of making Compound 38,

or a pharmaceutically acceptable salt thereof,

wherein:

Compound 38 has an enantiomeric excess of Compound A,

of least about 98.0%;

comprising a synthetic process of preparing an intermediate compound, wherein the intermediate compound is Formula (XIa),

or a hydrate or a solvate thereof,

wherein the intermediate compound has an enantiomeric excess of a compound of Formula (XI),

or a hydrate or a solvate thereof,

of at least about 80.0%; wherein the process of preparing the intermediate compound, comprises contacting a compound of Formula (XII),

or a solvate thereof, with:

a) CH 2 I 2 , Et 2 Zn, ZnI 2 , and an enantioselectivity inducer of Formula (XV) or its enantiomer,

or a solvate thereof,

such that the intermediate compound is prepared; or

b) (i) an enantioselectivity inducer of Formula (XIII),

or a solvate thereof,

in a solution in the presence of CH 2 I 2 and Et 2 Zn to form a reaction product of the compound of Formula (XII), or a solvate thereof; and

 (ii) subsequently, contacting the solution of step (i) with H 2 O 2 , such that the compound of Formula (XI) or a solvate thereof is prepared; or

c) an enantioselectivity inducer of Formula (XIV) or its enantiomer,

or a solvate thereof,

in the presence of CH 2 I 2 and dialkylzinc such that the intermediate compound is prepared,

wherein the entire method of making Compound 38 comprises only a single synthetic step to produce the compound of Formula (XI).

2. The method of claim 1 , wherein the process of preparing the intermediate compound, comprises:

contacting a compound of Formula (XII),

or a solvate thereof,

with CH 2 I 2 , Et 2 Zn, ZnI 2 , and the enantioselectivity inducer of Formula (XV) or its enantiomer,

or a solvate thereof,

such that the intermediate compound is prepared.

3. The method of claim 2 , wherein the enantioselectivity inducer or a solvate thereof, is

or a solvate thereof.

4. The method of claim 1 , wherein the process of preparing the intermediate compound, comprises:

(i) contacting a compound of Formula (XII),

or a solvate thereof,

with the enantioselectivity inducer of Formula (XIII),

or a solvate thereof,

in a solution in the presence of CH 2 I 2 and Et 2 Zn to form a reaction product of the compound of Formula (XII), or a solvate thereof; and

(ii) subsequently, contacting the solution of step (i) with H 2 O 2 , such that the compound of Formula (XI) or a solvate thereof is prepared.

5. The method of claim 1 , wherein the process of preparing the intermediate compound, comprises:

contacting a compound of Formula (XII),

or a solvate thereof,

with the enantioselectivity inducer of Formula (XIV) or its enantiomer,

or a solvate thereof,

in the presence of CH 2 I 2 and dialkylzinc such that the intermediate compound is prepared.

6. The method of claim 2 , wherein the ZnI 2 is formed by reacting Et 2 Zn with I 2 .

7. A method of synthesizing and working-up a compound of, Formula (XI),

or a hydrate or a solvate thereof,

having an enantiomeric excess of at least about 85% over its enantiomer wherein the of Formula (XI) compound is prepared by a process comprising:

contacting a compound of Formula (XII),

or a solvate thereof,

a) CH 2 I 2 , Et 2 Zn, ZnI 2 , and an enantioselectivity inducer of Formula (XV) or its enantiomer,

or a solvate thereof,

such that the compound of Formula (XI) is prepared; or

b) (i) an enantioselectivity inducer of Formula (XIII),

or a solvate thereof,

in a solution in the presence of CH 2 I 2 and Et 2 Zn to form a reaction product of the compound of Formula (XII), or a solvate thereof; and

 (ii) subsequently, contacting the solution of step (i) with H 2 O 2 , such that the compound of Formula (XI) or a solvate thereof is prepared; or

c) an enantioselectivity inducer of Formula (XIV) or its enantiomer,

or a solvate thereof,

in the presence of CH 2 I 2 and dialkylzinc such that the compound of Formula (XI) is prepared,

wherein the synthesis and work-up comprise a single synthetic step.

8. The method of claim 7 , wherein the compound is present in an enantiomeric excess is at least about 98.0% over its enantiomer.

9. The method of claim 7 , wherein the compound is synthesized and worked-up by a process comprising:

contacting a compound of Formula (XII),

or a solvate thereof,

with CH 2 I 2 , Et 2 Zn, ZnI 2 , and the enantioselectivity inducer of Formula (XV) or its enantiomer,

or a solvate thereof,

such that the compound is prepared.

10. The method of claim 9 , wherein the enantioselectivity inducer is

or a solvate thereof.

11. The method of claim 7 , wherein the compound is synthesized and worked-up by a process comprising:

(i) contacting a compound of Formula (XII),

or a solvate thereof,

with the enantioselectivity inducer of Formula (XIII),

or a solvate thereof,

in a solution in the presence of CH 2 I 2 and Et 2 Zn to form a reaction product of the compound of Formula (XII), or a solvate thereof; and

(ii) subsequently, contacting the solution of step (i) with H 2 O 2 , such that the compound of Formula (XI) or a solvate thereof is prepared.

12. The method of claim 7 , wherein the compound is synthesized and worked-up by a process comprising:

contacting a compound of Formula (XII),

or a solvate thereof,

with the enantioselectivity inducer of Formula (XIV) or its enantiomer,

or a solvate thereof,

in the presence of CH 2 I 2 and dialkylzinc such that the compound of claim 7 is prepared.

13. The method of claim 9 , wherein the ZnI 2 is formed by reacting Et 2 Zn with I 2 .

14. The method of claim 1 , further comprising purification of the compound of Formula (XI), wherein said purification comprises recrystallization.

15. The method of claim 4 , further comprising purification of the compound of Formula (XI), wherein said purification consists of solvent stripping, filtration, extraction, distillation, evaporation, recrystallization, or combinations thereof.

16. The method of claim 7 , wherein said working-up comprises purification of the compound of Formula (XI), wherein said purification comprises recrystallization.

17. The method of claim 11 , wherein said working-up comprises purification of the compound of Formula (XI), wherein said purification consists of solvent stripping, filtration, extraction, distillation, evaporation, recrystallization, or combinations thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: CHANDRARATNA, ROSHANTHA A.
To: IO THERAPEUTICS, INC.
Reel/Frame 047731/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: VULIGONDA, VIDYASAGAR PRADEEP
To: IO THERAPEUTICS, INC.
Reel/Frame 047731/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: JACKS, THOMAS; WADE, PETER; THOMPSON, ANDREW
To: J-STAR RESEARCH, INC.
Reel/Frame 047731/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: J-STAR RESEARCH, INC.
To: IO THERAPEUTICS, INC.
Reel/Frame 047731/0760 →
Continuity (3)
Provisional Application 62671137 · May 14, 2018
Provisional Application 62588163 · Nov 17, 2017
Related Publication 20190152888A1 · May 23, 2019
Cited By (2)
US 12,325,685 US 12,383,521